Compare STTK & EVEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | EVEX |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 792.9M | 888.2M |
| IPO Year | 2020 | 2020 |
| Metric | STTK | EVEX |
|---|---|---|
| Price | $6.85 | $2.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $10.00 | $6.88 |
| AVG Volume (30 Days) | 773.5K | ★ 806.9K |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.02 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11,676.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.59 | $2.10 |
| 52 Week High | $8.33 | $5.16 |
| Indicator | STTK | EVEX |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 36.95 |
| Support Level | $5.87 | $2.15 |
| Resistance Level | $7.75 | $2.81 |
| Average True Range (ATR) | 0.34 | 0.13 |
| MACD | -0.12 | -0.05 |
| Stochastic Oscillator | 11.51 | 16.25 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Eve Holding Inc is a provider of Urban Air Mobility solutions. The company's operating segments are; eVTOL that includes; the design and production of electric vertical take-off and landing vehicles (eVTOLs) including fixed wing and helicopter operators, as well as lessors that purchase and manage aircraft on behalf of operators; Service and Operations Solutions segment which includes a portfolio of maintenance and support services focused on its and third-party eVTOLs; and the UATM segment, a new Urban Air Traffic Management system designed to allow eVTOLs to operate safely and efficiently in dense urban airspace alongside conventional aircraft and drones.